Tango Therapeutics, Inc. (TNGX) Stock
Key stats
- Market cap
- $4.36B
- Price / Earnings ratio
- -19.8x
- EPS (TTM)
- -$1.38
- Volume
- Loading
- 52-week high
- $34.39
- 52-week low
- $7.49
Source: third-party data provider, as of November 13, 2026
Compare with TNGX
Recent news

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
TNGX

Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
TNGX

Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
TNGX

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
TNGX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 58.44
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.23
- SMA 50
- $23.42
- Price above SMA 50
- EMA 50
- $23.71
- Price above EMA 50
- SMA 200
- $22.76
- Price above SMA 200
- EMA 200
- $20.94
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.32 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
TNGX

Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
TNGX

Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
TNGX

Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
TNGX

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
TNGX

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
TNGX

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
TNGX

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
TNGX

Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
TNGX

Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Tango Therapeutics, Inc.
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Malte Peters M.D. | President, CEO & Director | 1962 |
| Mr. Matthew Gall M.B.A. | Chief Financial Officer | 1977 |
| Dr. Barbara L. Weber M.D. | Executive Officer | 1957 |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research & Development | 1977 |
| Prof. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board | 1961 |
| Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board | 1958 |
| Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board | 1967 |
| Mr. Jannik N. Andersen Ph.D. | Chief Scientific Officer | — |
| Ms. Elizabeth Pingpank Hickin | VP of IR & Corporate Communications | — |
| Ms. Julie Fogarty | Senior VP, General Counsel & Corporate Secretary | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 58.44
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.23
- SMA 50
- $23.42
- Price above SMA 50
- EMA 50
- $23.71
- Price above EMA 50
- SMA 200
- $22.76
- Price above SMA 200
- EMA 200
- $20.94
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $51.33
- High
- $67.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -23.2 | +9.4 | ||||||||||
| 2022 | -22.0 | -0.7 | -20.0 | -1.7 | -10.0 | -30.5 | -13.9 | +7.6 | -15.0 | +135.8 | -4.1 | -6.2 |
| 2023 | -9.7 | -23.6 | -24.0 | -22.0 | -18.9 | +24.3 | +7.3 | +99.1 | +57.3 | -25.3 | -7.4 | +27.6 |
| 2024 | +17.7 | -9.4 | -30.6 | +0.8 | -4.9 | +22.6 | +9.4 | +25.2 | -29.6 | -25.3 | -23.5 | -20.6 |
| 2025 | -4.8 | -28.9 | -27.9 | +10.2 | +57.4 | +101.6 | +11.0 | +2.8 | +26.1 | +1.6 | +36.2 | -15.0 |
| 2026 | +30.0 | -6.7 | +81.4 | +1.9 | +4.8 | +35.3 | -5.4 | -16.1 | +11.6 | -7.1 | +18.2 |



